SanBio Co., Ltd., which is in the development phase, focuses on regenerative cell medicines. The company is advancing development of its propriety regenerative cell medicine product SB623 for treating central nervous system disorders, mainly focusing on programs targeting chronic motor deficit from ischemic stroke and from traumatic brain injury (TBI).
In 2014 the company verified data on safety and efficacy suggesting possible recovery from disabilities from a phase 1/2a clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke conducted in the U.S. In addition, the company completed patient enrollment for a phase 2b clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke conducted in the U.S. in 2017, and a global phase 2 clinical trial of SB623 for treating chronic motor deficit from TBI conducted in Japan and the U.S. in 2018. The company is currently conducting clinical trials toward delivering a product in the market.
SanBio aims to become a global leader in the field of regenerative cell medicine.